Literature DB >> 30565312

Enhanced oxidative stress and the treatment by edaravone in mice model of amyotrophic lateral sclerosis.

Yasuyuki Ohta1, Emi Nomura1, Jingwei Shang1, Tian Feng1, Yong Huang1, Xia Liu1, Xiaowen Shi1, Yumiko Nakano1, Nozomi Hishikawa1, Kota Sato1, Mami Takemoto1, Toru Yamashita1, Koji Abe1.   

Abstract

Oxidative stress is associated with the degeneration of both motor neurons and skeletal muscles in amyotrophic lateral sclerosis (ALS). A free radical scavenger edaravone has been proven as a therapeutic drug for ALS patients, but the neuroprotective mechanism for the oxidative stress of ALS has not been fully investigated. In this study, we investigated oxidative stress in ALS model mice bearing both oxidative stress sensor nuclear erythroid 2-related factor 2 (Nrf2) and G93A-human Cu/Zn superoxide dismutase (Nrf2/G93A) treated by edaravone. In vivo Nrf2 imaging analysis showed the accelerated oxidative stress both in spinal motor neurons and lower limb muscles of Nrf2/G93A mice according to disease progression in addition to the enhancement of serum oxidative stress marker dROMS. These were significantly alleviated by edaravone treatment accompanied by clinical improvements (rotarod test). The present study suggests that in vivo optical imaging of Nrf2 is useful for detecting oxidative stress in ALS, and edaravone alleviates the degeneration of both motor neurons and muscles related to oxidative stress in ALS patients.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  ALS; SOD1; edaravone; in vivo imaging; nrf2; oxidative stress

Year:  2018        PMID: 30565312     DOI: 10.1002/jnr.24368

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  8 in total

1.  In Vivo Imaging of Oxidative and Hypoxic Stresses in Mice Model of Amyotrophic Lateral Sclerosis.

Authors:  Yasuyuki Ohta; Emi Nomura; Shinae Kizaka-Kondoh; Koji Abe
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Adipose-Derived Mesenchymal Stem Cells Combined With Extracellular Vesicles May Improve Amyotrophic Lateral Sclerosis.

Authors:  Xichen Wang; Yong Zhang; Tian Jin; Benson O A Botchway; Ruihua Fan; Lvxia Wang; Xuehong Liu
Journal:  Front Aging Neurosci       Date:  2022-05-18       Impact factor: 5.702

3.  Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cells.

Authors:  Qian Li; Yi Feng; Yingchao Xue; Xiping Zhan; Yi Fu; Gege Gui; Weiqiang Zhou; Jean-Philippe Richard; Arens Taga; Pan Li; Xiaobo Mao; Nicholas J Maragakis; Mingyao Ying
Journal:  Mol Neurodegener       Date:  2022-01-10       Impact factor: 14.195

4.  NU-9 improves health of hSOD1G93A mouse upper motor neurons in vitro, especially in combination with riluzole or edaravone.

Authors:  Barış Genç; Mukesh Gautam; Benjamin R Helmold; Nuran Koçak; Aksu Günay; Gashaw M Goshu; Richard B Silverman; P Hande Ozdinler
Journal:  Sci Rep       Date:  2022-03-30       Impact factor: 4.379

Review 5.  Activation of the Nrf2 Pathway as a Therapeutic Strategy for ALS Treatment.

Authors:  Liaisan Arslanbaeva; Marco Bisaglia
Journal:  Molecules       Date:  2022-02-22       Impact factor: 4.411

6.  The Protective Effect of Edaravone on TDP-43 Plus Oxidative Stress-Induced Neurotoxicity in Neuronal Cells: Analysis of Its Neuroprotective Mechanisms Using RNA Sequencing.

Authors:  Aki Soejima-Kusunoki; Kinya Okada; Ryuta Saito; Kazuhiko Watabe
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-08

7.  4-Phenylbutyric Acid (4-PBA) Derivatives Prevent SOD1 Amyloid Aggregation In Vitro with No Effect on Disease Progression in SOD1-ALS Mice.

Authors:  Leenor Alfahel; Shirel Argueti-Ostrovsky; Shir Barel; Mahmood Ali Saleh; Joy Kahn; Salome Azoulay-Ginsburg; Ayelet Rothstein; Simon Ebbinghaus; Arie Gruzman; Adrian Israelson
Journal:  Int J Mol Sci       Date:  2022-08-20       Impact factor: 6.208

8.  MicroRNA-183-5p protects human derived cell line SH-SY5Y cells from mepivacaine-induced injury.

Authors:  Qian Zhou; Ling Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.